(ATGE) Adtalem Global Education - Ratings and Ratios

Adtalem Global Education Inc. is a leading provider of workforce solutions worldwide, operating through three distinct segments: Chamberlain, Walden, and Medical and Veterinary. The company offers a wide range of degree and non-degree programs, catering to various industries such as medical, nursing, health professions, and veterinary postsecondary education, as well as counseling, business, psychology, and public administration. With a strong presence in the education sector, Adtalem operates several renowned institutions, including Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.

From a technical analysis perspective, ATGEs stock price is currently at $128.23, slightly below its 20-day Simple Moving Average (SMA) of $130.95, indicating a potential short-term bearish trend. However, the stock is above its 50-day SMA of $115.59 and 200-day SMA of $94.76, suggesting a longer-term bullish trend. The Average True Range (ATR) of 4.61 (3.60%) indicates moderate volatility. With the 52-week high and low at $136.25 and $63.03, respectively, the stock has shown significant price movement in the past year.

Fundamentally, Adtalem Global Education Inc. has a market capitalization of $4.66 billion and a Price-to-Earnings (P/E) ratio of 21.96, indicating a relatively stable valuation. The forward P/E ratio is 17.67, suggesting expected earnings growth. The companys Return on Equity (RoE) is 16.50, demonstrating a decent level of profitability. With a strong brand presence and diversified portfolio of educational programs, Adtalem is well-positioned for growth.

Based on the technical and fundamental data, a forecast for ATGE can be made. With the current price at $128.23 and resistance levels at $128.9 and $133.6, the stock may face a short-term challenge in breaking through these levels. However, with a strong fundamental outlook and a bullish longer-term trend, the stock is likely to continue its upward trajectory. A potential target price could be around $140-$145, representing a 10-12% increase from the current price. Conversely, a drop below the support level of $106.2 could indicate a more significant correction, potentially down to $99.5 or lower.